Matthew Rabinowitz, Ph.D.
Chief Executive Officer
Dr. Matthew Rabinowitz has had dual careers in industry and academia. While completing his dissertation, Dr. Rabinowitz co-founded an intelligent online merchandizing company, Panop.com, which later sold for $100M. Shortly after, Dr. Rabinowitz started his second company, Rosum, which developed a location technology using TV signals to augment GPS. He received the World Economic Forum “Technology Pioneers” award for founding Rosum and Natera.
In 2003, Dr. Rabinowitz’s life took a turn; a family member had a child born with a genetic disease, and the child passed away in infancy. Dr. Rabinowitz experienced firsthand the trauma, stress, and devastation that an unexpected diagnosis of genetic disease can bring to a family and was moved to action.
Drawing on expertise from his seemingly unrelated background, Dr. Rabinowitz embarked on a journey to ensure that other families need not experience similar pain. Through a team of experts in medicine, engineering, statistics, and genetics, along with Dr. Rabinowitz's own skills in optimization, signal processing, informatics, and entrepreneurship – Natera was born. Natera’s results have been remarkable; Dr. Rabinowitz and the entire Natera team are dedicated to bringing breakthrough technology to all.
Dr. Rabinowitz is now an authority in the field of prenatal and preconception informatics-based genetic testing. He has served as the Principal Investigator on six research grants awarded by the National Institutes of Health. Multiple publications have emerged in leading journals including Bioinformatics, Human Reproduction, and Molecular Human Reproduction. He actively presents at medical conferences around the world, including at the annual meeting of the American College of Medical Genetics, American Society of Reproductive Medicine, and Fetal Medicine Foundation World Congress.
Dr. Rabinowitz is a board member, advisor, and angel investor for multiple companies in biotechnology, communications, cleantech and healthcare. He has received the Scott Helt Memorial Award from IEEE and was selected by MIT Technology Review Magazine as one of the top 35 technology innovators under 35 in the United States.
Dr. Rabinowitz completed his B.A., M.Sc. and Ph.D. degrees at Stanford University, receiving both the Levin and Terman Awards — the highest academic honors offered in engineering and physics — and a graduate fellowship to the school of engineering.
Jonathan Sheena, M.Eng.
Chief Technology Officer
Mr. Sheena is a co-founder of Natera and an experienced entrepreneur with proven success in technology innovation. Prior to Natera, Mr. Sheena co-founded PocketThis which sold cutting edge server technology to mobile networks worldwide. While a graduate student at MIT, and in partnership with the Associated Press, Reuters, Knight Ridder, ABC, and the New York Times, he architected the first web-based personalized newspaper called “Fishwrap.” The technology was licensed by and deployed to newspapers worldwide, including the San Francisco Chronicle. After MIT, Mr. Sheena worked as a software architect at Firefly, an online community, personalization and collaborative filtering company. After Firefly was purchased by Microsoft, he brought online the largest running personalization and online identity system used by tens of millions of people worldwide. Mr. Sheena’s background is in personalization technology. He holds both M.Eng. and B.S. degrees from MIT as well as a number of patents in internet and mobile technology.
Herm Rosenman, M.B.A.
Chief Financial Officer
Mr. Rosenman is an experienced executive in senior operations and financial roles. He was Senior Vice President-Finance & CFO at Gen-Probe Incorporated from June 2001 until its sale to Hologic in August, 2012. From 1997 to 2000, Mr. Rosenman was President and Chief Executive Officer of Ultra Acquisition Corp., a retail chain and consumer products manufacturer. He was President and Chief Executive Officer of RadNet Management, Inc., a large diagnostic imaging provider, as well as Executive Vice President & Chief Financial Officer of Rexene Corp., a petrochemicals industry Fortune 1000 company. Mr. Rosenman was also a partner at Coopers & Lybrand (now PricewaterhouseCoopers LLP) where he served numerous Fortune 1000 clients, principally in the pharmaceuticals and telecommunications industries. He received a B.B.A. in finance and accounting from Pace College (now Pace University) and an M.B.A. in finance from the Wharton School of the University of Pennsylvania. Mr. Rosenman currently serves on the Board of Directors of Oxford Immunotec, Ltd., Vivus, Inc. and Renaissance Rx.
Daniel Rabinowitz, LL.M.
Secretary and General Counsel
Mr. Rabinowitz is Secretary and General Counsel of Natera. Prior to joining Natera, he was a corporate partner at the law firm McDermott, Will & Emery, and, before that, was also a corporate lawyer at the law firm Davis Polk & Wardwell. He has worked in the United States and Europe advising domestic, foreign, public, and private companies on capital raisings, M&A, investment management and compliance with US federal and state securities law. He has studied genetics, biochemistry, and molecular biology at Harvard University Extension School and attended courses on the legal and ethical aspects of biotechnology at Harvard Law School. Mr. Rabinowitz completed his B.A. and LL.B. degrees at the University of the Witwatersrand, South Africa, graduating at the top of his law school class, and completed his LL.M. at New York University School of Law with both Rotary Foundation and Fulbright Scholarships.
Jimmy Lin MD, PhD, MHS
Chief Scientific Officer, Oncology
Dr. Cheng-Ho Jimmy Lin joins Natera coming from a long history as a pioneer in cancer genomics. Most recently, he led the clinical genomics program at the National Cancer Institute (NCI) at the National Institutes of Health (NIH). Previously, at Johns Hopkins and Washington University in St. Louis, Dr. Lin was part of one of the first clinical genomics labs in academia and led the computational analyses of the first ever exome sequencing studies in cancer, including breast, colorectal, pancreatic, glioblastoma, medulloblastoma, and melanoma. He has published in top academic journals, such as Science, Nature, and Cell, and has been an expert in national and international media outlets, such as New York Times, Forbes, Bloomberg Businessweek, Washington Post, and the Financial Times. Dr. Lin holds an MHS in Bioinformatics, a PhD in Cellular and Molecular Medicine, and an MD from Johns Hopkins University as well dual majors in Cognitive Science and Molecular Biophysics and Biochemistry from Yale University.
Senior Vice President, Commercial Operations
Mr. Chapman began his career in the Department of Human Genetics at UCLA, where he contributed to the selection process and design of oligonucleotide arrays used to identify SNPs associated with multiple sclerosis. After leaving UCLA, Mr. Chapman worked in a commercial role with Genzyme Genetics, where his team was responsible for prenatal and preconception genetic testing revenues nearing $100 million. During his time at Genzyme, Mr. Chapman’s efforts reshaped the way medicine is practiced when he led Genzyme’s sales initiative into population screening for Fragile X Syndrome. He established the largest global network of physicians who routinely screen for the disorder, and radically altered the way the test is offered. In 2005, he elevated carrier screening for Spinal Muscular Atrophy (SMA) to the forefront of business development efforts at Genzyme, playing a critical role in the groundbreaking launch of SMA carrier screening. Today, SMA screening is recommended by the ACMG and is routinely offered to couples across the United States. At Genzyme, Mr. Chapman was the direct recipient of 27 sales awards and was a two-time winner of the prestigious Alpine Award, which recognizes outstanding achievement and innovation. Since joining Natera in 2010, he has been responsible for building Natera’s sales and managed-care teams and has also led the commercial team. He has also overseen the successful launch of five products and the establishment of the premier worldwide distribution network for noninvasive prenatal testing. Mr. Chapman graduated with honors and holds a B.S. in Microbiology, Immunology, and Molecular Genetics from University of California, Los Angeles.
Vice President, Legal and Corporate Affairs
Mr. Leichter has been negotiating and executing on deals in the life sciences industry for over 15 years. Prior to joining Natera, Mr. Leichter held positions of increasing responsibility at Cubist Pharmaceuticals during a period when revenues and market capitalization grew by more than ten-fold. At Cubist, Mr.Leichter’s responsibilities included M&A, other business development and technical operations transactions, and SEC reporting. Mr. Leichter began his legal career as an Associate at the law firm of Palmer & Dodge, LLP, where he advised life sciences, hi-tech and other companies on complex transactions and litigation. Mr. Leichter received his J.D., cum laude, from the University of Michigan School of Law and a B.A. in Economics from Wesleyan University.
Solomon Moshkevich, M.B.A.
Vice President, Product and Strategy
Mr. Moshkevich is passionate about improving patient outcomes and lowering healthcare costs through non-invasive technologies and innovative reimbursement models. He began his career in New York as a consultant with Bain & Company, and then moved to Moscow, Russia in 2007 to lead a regional growth strategy for SABMiller. Returning to Boston, he joined the investment team at Parthenon Capital Partners where he invested in healthcare and business services companies. Later with the Disease Management team of OptumHealth (a UnitedHealth Group company), he was the first to identify and measure the value of provider engagement in Optum’s disease management services, which led to lower costs and improved patient outcomes. More recently, as a member of the start-up team at Organ-I, he developed a commercialization strategy for a non-invasive genetic test that detects the acute rejection of solid organ transplants. Since joining Natera in 2011, he has been responsible for launching Natera’s brands in more than 40 countries worldwide, and developing key channel partnerships in the United States. Mr. Moshkevich graduated summa cum laude from Columbia University with a B.A. in Economics and Mathematics and has an M.B.A. from Stanford University.
Styrmir Sigurjonsson, Ph.D.
Vice President, Statistics
Dr. Sigurjonsson's expertise is in the areas of probabilistic modeling and statistics. Prior to Natera, Dr. Sigurjonsson held various positions in the financial services sector. He developed probability of default models in fixed income at Citi's investment bank. He later joined Straumur Investment where he founded a quantitative trading desk and ran the domestic derivatives desk. Dr. Sigurjonsson has broad experience in developing statistical models and algorithms for critical real-world applications. He received his C.S. in Electrical and Computer Engineering from the University of Iceland, M.S. and Ph.D. in Electrical Engineering from Stanford University. At Stanford University he was a member of the Information Theory Group where he conducted research in the areas of estimation, information theory and probability.
Damon Silvestry, M.Eng.
Senior Vice President, Operations
Prior to joining Natera, Mr. Silvestry was the Senior Vice President of Operations for Miraca Life Sciences, a leading, academic-caliber anatomic pathology laboratory, providing diagnostic services in the fields of dermatology, gastroenterology, hematology, urology, and breast health. Prior to Miraca, Damon had a distinguished career at Dell, Inc., serving as the Executive Director for Latin America & Canada Sales Operations, Director of Dell Americas Engineering, Senior Manager of New Product Introductions and various leadership roles within engineering. Before Dell, Mr. Silvestry was the New Products Manufacturing Engineer for Symbol Technologies Incorporated (Motorola). Additionally, he served as a nuclear weapons specialist and worked on several major munition systems including the Peacekeeper missile in the United States Air Force.
Mr. Silvestry received his master’s degree in Manufacturing Engineering from NYU Polytechnic. Mr. Silvestry also holds a bachelor’s degree in Industrial Engineering from Southern Illinois University. He is a Certified CAP inspector and holds a Black Belt Certification in 6 Sigma. Damon was the past President of the Board of Directors for Austin Habitat for Humanity.
Phil Grinnell, M.B.A.
Vice President of Sales
Phil Grinnell holds a B.S in Corporate Communications from the University of Texas at Austin and a M.B.A from Villanova University. His career in genetic testing began with Athena Diagnostics in 2005, where he rose to the position of Mid-Atlantic Regional Sales Manager winning multiple awards. He joined Natera in 2011 and, as Eastern Regional Sales Director, oversaw the build out of Natera’s sales force and the successful launch of Natera's Non Invasive Prenatal Test, Panorama®. Most recently, Phil served as Natera's Senior Director of Sales Operations, responsible for Sales Training, Analytics, Inside Sales, and User Experience.
Mike Brophy, M.B.A.
Vice President, Corporate Development
Mike Brophy received a Bachelor of Science degree in Economics from the United States Air Force Academy, where he was a four year letterman and team captain, NCAA Division 1 men’s soccer. He went on to receive a Master of Business Administration degree from UCLA. His military career included leading a multi-agency, 10-person team on a $1.4 billion contract to modernize 10 remote satellite tracking stations worldwide. He achieved the rank of captain during his four years of active duty and was one of the youngest officers ever to be granted space-systems level contracting authority.
Ramesh Hariharan Ph.D., M.B.A.
Vice President, Marketing and Medical Education
Dr. Ramesh Hariharan’s career of 18 years spans a range of subspecialties, including basic research, strategic management consulting, and marketing. At GE’s Basic Research Center, he was nominated as the Best Young Scientist for his innovations, which included the discovery of a new molecule that was commercialized to enable higher data densities in rewritable DVDs, and a novel process for agglomerating nanoparticles. At McKinsey, he served biotech, pharma, medical device, diagnostics, and private equity leaders in the U.S., Germany, and the U.K., tackling a wide range of business issues such as product launches, market expansion, life cycle strategies, and business turnarounds. Dr. Hariharan then held marketing leadership positions in Oncology, Women’s Health, and Vaccines at Novartis, Abbott/AbbVie and Biotheranostics. Most recently at Biotheranostics, he drove the successful commercial turnaround and relaunch of Breast Cancer Index and CancerTYPE ID including repositioning, branding, messaging, and targeted promotions to medical oncologists and patients. He received a bachelor’s degree in chemical engineering from IIT Bombay, a Ph.D. in chemical engineering from Princeton University, and an MBA from MIT Sloan School of Management.